Etoposide Injection IP 100 MG
VEPELIEVA Etoposide Injection IP 100MG is a widely used anticancer chemotherapy medicine formulated for the treatment of different types of cancers. It contains Etoposide, an effective oncology medicine that helps slow down or stop the growth of cancer cells in the body. This injection is commonly used in hospitals, cancer treatment centers, and oncology clinics under the supervision of experienced healthcare professionals.
Etoposide belongs to a class of medicines known as topoisomerase inhibitors. It works by interfering with the DNA replication process of rapidly growing cancer cells. By damaging the DNA of these abnormal cells, the medicine helps prevent their growth and spread. Due to its effectiveness in chemotherapy treatment protocols, Etoposide Injection IP 100MG is commonly prescribed in combination with other anticancer medicines for better treatment outcomes.
VEPELIEVA is manufactured under high pharmaceutical quality standards to ensure safety, purity, and effectiveness. The medicine is designed to meet the requirements of modern oncology treatment and is trusted by healthcare professionals for use in multiple cancer therapies.
This oncology injection is mainly recommended for patients diagnosed with cancers such as small cell lung cancer, testicular cancer, leukemia, lymphoma, and other severe malignant conditions. Doctors may prescribe this medicine alone or as part of combination chemotherapy depending on the patient’s medical condition, stage of cancer, and overall treatment plan.
Chemotherapy medicines like VEPELIEVA are an important part of cancer management because they help reduce the spread of cancer cells and improve the effectiveness of treatment protocols. Since cancer cells multiply rapidly, medicines like Etoposide are specially designed to target these abnormal cells and reduce their growth inside the body.
VEPELIEVA Etoposide Injection IP 100MG is intended strictly for medical use and should only be administered by trained healthcare professionals in clinical settings. Patients are advised not to self-administer this injection. Proper medical monitoring, laboratory testing, and regular health assessments are usually recommended during chemotherapy treatment to ensure patient safety and better treatment response.
This anticancer injection is known for its role in advanced oncology treatment plans and is considered an important chemotherapy medicine in cancer care. With proper medical supervision and supportive care, Etoposide Injection can help improve treatment management in cancer patients.
View Details
Capecitabine Dispersible Tablets 500mg
CAPELIEVA-DT 500 mg contains Capecitabine, an oral fluoropyrimidine chemotherapy drug. It is a prodrug that converts into 5-Fluorouracil (5-FU) inside tumor cells, where it interferes with DNA synthesis and inhibits cancer cell growth.
The dispersible (DT) form is helpful for patients who have difficulty swallowing tablets.
View Details
Irinotecan Hydrochloride Injection IP 100mg
IRILIEVA 100 mg contains Irinotecan Hydrochloride, a topoisomerase I inhibitor anticancer drug. It works by preventing DNA replication in rapidly dividing cancer cells, leading to cell death.
View Details
Topotecan Injection IP 2.5mg
HYCALIEVA 2.5 mg contains Topotecan, a topoisomerase-I inhibitor belonging to the camptothecin class. It works by stabilizing the topoisomerase-I–DNA complex, causing DNA strand breaks and preventing DNA replication, leading to cancer cell death.
View Details
Doxorubicin Hydrochloride iInjection IP 50mg
DOXLIEVA 50 mg contains Doxorubicin Hydrochloride, an anthracycline antitumor antibiotic. It acts by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis of cancer cells. It is a backbone drug in many chemotherapy regimens.
View Details
Dactinomycin for Injection USP 0.5MG
DACTOLIEVA 0.5 mg contains Dactinomycin (Actinomycin D), an antitumor antibiotic. It works by intercalating into DNA, thereby inhibiting RNA synthesis and blocking protein production, leading to cancer cell death. It is especially effective in pediatric and germ cell tumors.
View Details
Vinorelbine Injection IP 50mg
NAVELIEVA 50 mg contains Vinorelbine, a semi-synthetic vinca alkaloid. It inhibits microtubule assembly by binding to tubulin, thereby arresting cell division in the M phase of the cell cycle. It is primarily used in lung and breast cancers.
View Details
Fludarabine Phosphate for Injection 10mg
FLULIEVA 10 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. Inside the cell, it is converted to the active metabolite fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA synthesis and apoptosis. It is primarily used in hematological malignancies.
View Details
L-Asparaginase Injection 5000IU
L-GANASELIEVA 5,000 IU contains L-Asparaginase, an antineoplastic enzyme used mainly in leukemia treatment. It works by depleting the amino acid asparagine from the blood. Leukemic lymphoblasts cannot synthesize asparagine on their own, so depletion leads to inhibition of protein synthesis and cell death.
View Details
L-Asparaginase Injection 10000IU
L-GANASELIEVA 10,000 IU contains L-Asparaginase, an antineoplastic enzyme. It works by depleting asparagine, an amino acid essential for leukemic lymphoblasts. Normal cells can synthesize asparagine, but leukemic cells cannot—leading to selective tumor cell death.
View Details
Ifosfamide for Injection with Mesna 2g
IFOSLIEVA 2 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by neutralizing toxic metabolites (acrolein) in the urinary tract.
View Details
Ifosfamide for Injection with Mesna 1g
IFOSLIEVA 1 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by binding toxic uro-metabolites (acrolein) in the urinary tract.
View Details
